Combined full-year profits for the top 100 pharma companies dipped to 1.8% on the back of issues with the US Food and Drug Association, stringent price controls and a competitive global market among others, a PharmaBiz report showed.
Adjusted net sales for the top 100 companies increased by 7.2% to 1,712.01 billion rupees ($26.1 billion) from 1,597.47 billion rupees.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze